Results 21 to 30 of about 17,663 (255)

Is there a role for oral triple therapy in patients with acute coronary syndromes without atrial fibrillation? [PDF]

, 2018
© 2018 Bentham Science PublishersBACKGROUND: Acute coronary syndrome (ACS) patients, despite treatment with dual antiplatelet therapy (DAPT), have up to 10% risk of recurrent major adverse cardiac events (MACE) in the short term.
Akhtar, Zaki, Farag, Mohamed, Gorog, Diana Adrienne, Spinthakis, Nikolaos   +3 more
core   +2 more sources

Anticoagulants for acute ischaemic stroke [PDF]

, 2015
Peer reviewedPublisher ...
Counsell, Carl, Kane, Edward J, Sandercock, Peter A G   +2 more
core   +1 more source

Adaptation of New Oral Anticoagulants for Warfarin Anticoagulated Patient with Traumatic Ongoing Hemorrhage [PDF]

Journal of Acute Care Surgery, 2018
The traditional drug for anticoagulation in those with a high risk of thrombosis is a vitamin K antagonist, such as warfarin. On the other hand, this drug has several limitations and hemorrhagic complications.
Jin Bong Ye, Young Hoon Sul, Jin Young Lee, Seung Je Go, Jung Hee Choi   +4 more
doaj   +1 more source

Percutaneous Left Atrial Appendage Occlusion in Comparison to Non‐Vitamin K Antagonist Oral Anticoagulant Among Patients With Atrial Fibrillation

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022
Background This study aimed to compare percutaneous left atrial appendage occlusion (LAAO) with non‐vitamin K antagonist oral anticoagulants among patients with atrial fibrillation. Methods and Results Using a US administrative database, 562 850 patients
Peter A. Noseworthy, Holly K. Van Houten, Harlan M. Krumholz, David M. Kent, Neena S. Abraham, Jonathan Graff‐Radford, Mohamad Alkhouli, Henry J. Henk, Nilay D. Shah, Bernard J. Gersh, Paul A. Friedman, David R. Holmes, Xiaoxi Yao   +12 more
doaj   +1 more source

Current clinician perspective on non-vitamin K antagonist oral anticoagulant use in challenging clinical cases. [PDF]

, 2020
OBJECTIVE: The evolution of non-vitamin K antagonist anticoagulants (NOACs) has changed the horizon of stroke prevention in atrial fibrillation (SPAF).
Acar, RD, Akgün, T, Camm, AJ, Emren, V, Kanat, S, Karacağlar, E, Kepez, A, Kul, Ş, Tülüce, K, Türk, UÖ, Yakar Tülüce, S, Özel, E, Şimşek, E   +12 more
core   +1 more source

Apixaban Enhances Endogenous Fibrinolysis in Patients with Atrial Fibrillation [PDF]

, 2019
© The Author(s) 2019. Published by Oxford University Press on behalf of the European Society of Cardiology.AIMS: Approximately 20% of ischaemic stroke patients exhibit spontaneous arterial recanalization, attributable to endogenous fibrinolysis, which ...
Arachchillage, Deepa RJ, Farag, Mohamed, Gorog, Diana, Gue, Ying X., Lip, Gregory Y H, Spinthakis, Nikolaos, Srinivasan, Manivannan, Wellsted, David   +7 more
core   +3 more sources

Real-world cost-effectiveness analysis of NOACs versus VKA for stroke prevention in Spain.

PLoS ONE, 2022
AimsA Markov model was adapted to assess the real-world cost-effectiveness of rivaroxaban, dabigatran and apixaban. Each of these non-vitamin K antagonist oral anticoagulants was compared with vitamin K antagonist for stroke prevention in patients with ...
Carlos Escobar Cervantes, Julio Martí-Almor, Alejandro Isidoro Pérez Cabeza, Kevin Bowrin, Aleix Llorac Moix, Mar Genís Gironès, David Gasche, Aurélie Millier, Jean Tardu, Mondher Toumi, Jean-Baptiste Briere   +10 more
doaj   +2 more sources

Potentiation of thrombus instability: a contributory mechanism to the effectiveness of antithrombotic medications [PDF]

, 2018
© The Author(s) 2018The stability of an arterial thrombus, determined by its structure and ability to resist endogenous fibrinolysis, is a major determinant of the extent of infarction that results from coronary or cerebrovascular thrombosis.
A Gast, AD Michelson, B Labarthe, B Shen, C Patrono, CT Ammollo, D Capodanno, D Gailani, DA Gorog, Diana A. Gorog, DM Coenen, E Álvarez, ER Bates, F Kabirian, F Müller, F Semeraro, G Stephens, H Brogren, HE Speich, HE Speich, HJ Weiss, HJ Weiss, HR Baumgartner, J Zilberman-Rudenko, JD McFadyen, JI Weitz, JM Cosemans, JP Collet, JP Collet, K Hosokawa, K Nagatsuka, KS Sakariassen, L Valerio, LF Brass, M Cattaneo, M Farag, M Humbert, M Larsson, M Li, M Ungerer, MA Bailey, MI Furman, MJ Price, ML Montfoort von, MS Sabatine, P Andre, P Seizer, PA Borne von dem, PP Wadowski, R Hellmuth, R Nergiz-Unal, RA Ajjan, S Goto, S Goto, SA Shaya, SB Larsen, SJ Marciniak, T Heitzer, T Renné, VT Turitto, VT Turitto, WA Schumacher, WS Nesbitt, X Wang, Y Yano, YC Lau, ZM Ruggeri   +66 more
core   +2 more sources

Non-vitamin K antagonist oral anticoagulants and heart failure

Archives of Cardiovascular Diseases, 2016
Thromboembolism contributes to morbidity and mortality in patients with heart failure (HF), and atrial fibrillation (AF) is one of the main factors promoting this complication. As they share many risk factors, HF and AF frequently coexist, and patients with both conditions are at a particularly high risk of thromboembolism.
Isnard, R., Bauer, F., Cohen-Solal, A., Damy, T., Donal, Erwan, Galinier, M., Hagège, A., Jourdain, P., Leclercq, Christophe, Sabatier, Rodolphe, Trochu, Jean-Noël, Cohen, A.   +11 more
openaire   +3 more sources

Stroke prevention for non-valvular atrial fibrillation: how to make the right choice of directly acting oral anticoagulants?

Российский кардиологический журнал, 2019
Patients with atrial fibrillation have a high risk of developing stroke and death, which requires constant anticoagulant support. In this regard, the physician faces the difficult task of selecting the appropriate oral anticoagulant for patient with ...
N. N. Kryukov, E. V. Sayutina, A. M. Osadchuk, M. A. Osadchuk   +3 more
doaj   +1 more source